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The Diagnosis and Management of Small Renal Masses 
 
Small renal masses (SRMs) comprise an important part of most urologist’s 
workload. This special issue contains a series of evidenced-based papers written 
by leading experts in the field, covering all aspects of diagnosis and management 
of SRMs.  
 
A small renal mass is defined as one less than 4cm in size[1]. The incidence of 
SRMs has increased notably in the past few decades mainly related to the 
increased incidence of incidental masses identified following ultrasound or 
CT/MRI scans of the abdomen for unrelated reasons[1-3]. Renal cell carcinoma 
(RCC) is the most common type of tumour, accounting for 90% of all malignant 
kidney masses. RCC accounts for around 2-3% of all newly diagnosed cancers [4, 
5].  
 
Initially Elstob and colleagues detail how to assess the key features of small renal 
masses on imaging including how to assess whether it is benign or malignant, 
whether it shows signs of biological aggressiveness as well as the anatomical 
information that helps guide interventional and surgical management [2]. 
Contrast-enhanced CT has high diagnostic accuracy for the diagnosis of renal cell 
carcinoma and is the diagnostic modality of choice. Contrast-enhanced 
ultrasound and MRI are good techniques for indeterminate lesions or in patients 
who cannot have a CT scan. The key pre-and post-operative variables that 
determine prognosis for RCC are detailed in the special series paper by Crestani 
et al[1].   
 
Alongside the increased incidence of incidental SRMs there has been a stage and 
grade migration towards less advanced and less aggressive tumours at 
presentation. This has paved the way for a need to better characterise these 
lesions in order to make the most appropriate management decisions and reduce 
unnecessary harm to patients. Given that the majority of SRMs are benign 
tumours or RCCs with an indolent behaviour, renal biopsy plays an increasingly 
important role in differentiating malignant from benign tumours, as described in 
the special series paper by Leao et al[5]. Although historically there has been 
concern over the reliability of the information obtained, a reported 
contemporary diagnostic yield of 80-94% has led to increased acceptance that a 
renal tumour biopsy should be offered to many patients presenting with SRMs in 
whom treatment is being considered[5]. Many urologists now accept that all 
patients being considered for active surveillance or an ablative treatment should 
have a renal biopsy.  
 
As we now understand more about the natural history of SRMs, we know that 
they tend to grow slowly, with a reported average growth of approximately 
0.31cm/year[6, 7]. Given only 1-2% of patients on active surveillance develop 
metastatic disease during follow up, surveillance with repeat interval imaging is 
a good initial option for some patients with T1a disease, particularly those who 
do not want surgical treatment or who are unfit for it. As described by the special 
series paper by Volpe[6], delayed intervention can be offered to those whose 
masses have shown rapid growth.  However, nephron-sparing surgical treatment 
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with partial nephrectomy remains the standard of care for younger and fitter 
patients with SRMs and those with masses > 4cm. Excellent 10-year survival 
rates of over 95% have been shown with laparoscopic partial nephrectomy 
(LPN) for cT1a disease[8]. With comparable oncological outcomes to radical 
nephrectomy but improved renal function outcomes, partial nephrectomy has 
replaced radical nephrectomy as standard of care for uncomplicated SRMs 
where surgery is required. Developments to improve the cosmesis and 
morbidity associated with LPN have also been attempted and are described in 
the special series paper by Kim et al [9]. They include laparoendoscopic single-
site surgery (LESS) and natural orifice transluminal endoscopic surgery 
(NOTES). Both techniques are challenging and further evidence is required to 
consolidate their role in routine laparoscopic partial nephrectomy.   
 
In the past decade, robotic assisted laparoscopic partial nephrectomy (RALPN) 
has increased in popularity and it is likely to overtake LPN and open partial 
nephrectomy (OPN) as the most common method for partial nephrectomy in 
regions where the robot is accessible, despite the significant costs associated 
with robotic surgery. The key advantages appear to be a shorter learning curve 
and reduced warm ischaemic time, whilst the peri-operative and short-term 
outcomes of RALPN appear to be at least as good as LPN[10]. The short-term 
recovery and time taken to discharge home is quicker with LPN and RALPN 
compared to OPN. The long-term oncological outcomes of RALPN are still 
awaited, though early markers of surgical success such as positive margin rates 
are encouraging in experienced hands. Zhao et al[11] and Novara et al[10], in 
their special series papers, describe the techniques, key considerations and 
outcomes for LPN and RALPN respectively.  
 
OPN is still the preferred surgical modality in patients in whom LPN or RALPN 
approach would be difficult, for example, re-do partial nephrectomies, complex 
tumours (large or endophytic) and in those with multiple renal tumours (e.g. 
hereditary renal tumours).  It also allows ice cooling of the kidney in patients 
with impaired renal function. The indications, technique and considerations are 
detailed in the special series paper by Anastasiadis et al[12]. 
 
The increasing role of ablative treatments for SRMs, such as radiofrequency 
ablation (RFA) and cryotherapy are covered in this special series by Kelly et 
al[13] and Zondervan et al[14], respectively. Currently their use is indicated 
primarily in high co-morbidity and elderly patients not suitable for surgical 
treatment. Short-term morbidity profiles of percutaneous techniques are better 
than LPN, though long-term oncological outcomes are lacking. Medium term 
outcomes for cryotherapy have shown slightly higher local progression rates 
than LPN[14]. However, as with all ablative treatments for cancer surgery, as the 
technique is developed and optimised, it is important to collect long-term data 
on oncological outcomes. If favourable, ablative treatments would lend 
themselves to a more prominent role in patients with SRMs. 
 
To round off the special series, Raison et al[15] cover particularly challenging 
and unusual situations in partial nephrectomy that a urologist may encounter 
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and Caputo et al[16] discus how to deal with the complications arising from the 
procedure. 
 
The future is likely to see the widespread establishment of RALPN and 
technologies associated with this. The increase in the number of robots in the 
past 10 years[17]  defies conventional health economic arguments, which 
suggest the robot is here to stay. Cheaper platforms, which are more affordable, 
are imminent and eagerly awaited. As described by Malthouse et al[18], 
developments in RALPN are likely to take place in integrating imaging and 
navigation with augmented reality and inclusion of haptic and sensory 
capabilities. 
 
The management of the small renal mass present unique challenges to the 
modern urologist. From making an accurate diagnosis to selecting the 
appropriate treatment for each patient, this special edition provides a 
comprehensive guide from leading experts on all aspects of this often complex 
and multi-factorial clinical condition.  
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